M&A Values Continued To Decline During Q4 2024

 
• By Joseph Haas
  
M&A
Biopharma M&A valuation was down substantially during the fourth quarter compared to Q4 2023 • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Scrip